Methotrexate

• 

  Subject Areas on Research

  • 18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients. 
  • 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. 
  • 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. 
  • 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. 
  • 5-day methotrexate for women with metastatic gestational trophoblastic disease. 
  • A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. 
  • A mathematical model of the folate cycle: new insights into folate homeostasis. 
  • A novel high-performance liquid chromatography/mass spectrometry method for improved selective and sensitive measurement of methotrexate polyglutamation status in human red blood cells. 
  • A phase II study of piritrexim in patients with advanced squamous head and neck cancer. 
  • A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. 
  • A pilot study of low-dose cyclosporin for graft-versus-host prophylaxis in marrow transplantation. 
  • A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. 
  • A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis. 
  • A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy. 
  • A reappraisal of the results of stopping therapy in childhood leukemia. 
  • A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. 
  • A substrate specific functional polymorphism of human gamma-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells. 
  • A systematic review of morphea treatments and therapeutic algorithm. 
  • A trial of outpatient chemotherapy for recurrent head and neck tumors. 
  • Acute and chronic graft-versus-host disease in man. 
  • Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. 
  • Adjunctive adjuvant or neoadjuvant chemotherapy for locally advanced bladder cancer: a critical appraisal of the present status. 
  • Adjuvant chemotherapy for osteosarcoma may not increase survival after neoadjuvant chemotherapy and surgical resection. 
  • Adjuvant chemotherapy in older women with early-stage breast cancer. 
  • Adjuvant sequential chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil (ACMF) with concurrent radiotherapy in resectable advanced breast cancer. 
  • Advanced prostatic carcinoma: pulmonary manifestations. 
  • Alcohol consumption and the risk of mortality and myocardial infarction in patients with rheumatoid arthritis. 
  • Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT. 
  • Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. 
  • Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. 
  • Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis. 
  • Altered Folate Homeostasis in Children with Down Syndrome: A Potential Basis for Enhanced Methotrexate Toxicity. 
  • Alternating weekly chemotherapy with etoposide-methotrexate-dactinomycin/cyclophosphamide-vincristine for high-risk gestational trophoblastic disease. 
  • Ambulatory high-dose methotrexate administration among pediatric osteosarcoma patients in an urban, underserved setting is feasible, safe, and cost-effective. 
  • An immune tolerance approach using transient low-dose methotrexate in the ERT-naïve setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease. 
  • Analysis of intracellular methotrexate polyglutamates in patients with juvenile idiopathic arthritis: effect of route of administration on variability in intracellular methotrexate polyglutamate concentrations. 
  • Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201. 
  • Antirheumatic medications in pregnancy and breastfeeding. 
  • Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174? 
  • Association of anemia and physical disability among patients with rheumatoid arthritis. 
  • Association of methotrexate, rheumatoid arthritis and lymphoma: report of 2 cases and literature review. 
  • Basis for natural resistance to methotrexate in human acute non-lymphocytic leukemia. 
  • Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST). 
  • Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort. 
  • Bilateral episcleritis as a manifestation of cutaneous leukocytoclastic vasculitis. 
  • Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America. 
  • Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease. 
  • Breastfeeding in mothers with systemic lupus erythematosus. 
  • Brief report: effect of intravenous methotrexate dose and infusion rate on neuropsychological function one year after diagnosis of acute lymphoblastic leukemia. 
  • Cancer chemotherapeutic response and intravenous hyperalimentaion. 
  • Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre-Specified Analysis of Two Phase III Trials. 
  • Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. 
  • Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis. 
  • Chemotherapy-related changes in central nervous system phospholipids and neurocognitive function in childhood acute lymphoblastic leukemia. 
  • Childhood Arthritis and Rheumatology Research Alliance Consensus Clinical Treatment Plans for Juvenile Dermatomyositis with Persistent Skin Rash. 
  • Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans for Juvenile Idiopathic Arthritis-Associated and Idiopathic Chronic Anterior Uveitis. 
  • Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. 
  • Classification, presentation, and initial treatment of Wegener's granulomatosis in childhood. 
  • Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis. 
  • Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. 
  • Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. 
  • Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors. 
  • Clostridium septicum abscess in hepatic metastases: successful medical management. 
  • Co-occurrence of idiopathic granulomatous hepatitis and primary biliary cirrhosis. 
  • Collaborative multicenter investigation of marrow transplantation for sickle cell disease: current results and future directions. 
  • Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study. 
  • Combination chemotherapy for osteosarcoma. 
  • Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. 
  • Combined treatment approaches in regionally advanced bladder cancer. 
  • Comparing Presenting Clinical Features in 48 Children With Microscopic Polyangiitis to 183 Children Who Have Granulomatosis With Polyangiitis (Wegener's): An ARChiVe Cohort Study. 
  • Comparison of cytostatic sensitivities of L 1210 cells and human stimulated lymphocytes in three cell proliferation assays. 
  • Comparison of prednisolone, vincristine, methotrexate, and 6-mercaptopurine vs. vincristine and prednisone induction therapy in childhood acute leukemia. 
  • Conservative management of morbidly adherent placenta: expert review. 
  • Correlation of intralesional in vivo chemotherapy of line 10 hepatoma with in vitro drug sensitivity. 
  • Corticosteroids and methotrexate as adjuvants to costimulation blockade in non-human primate renal transplantation. 
  • Cost-effectiveness and cost-benefit analysis of using methotrexate vs Goeckerman therapy for psoriasis. A pilot study. 
  • Cost-effectiveness of methotrexate and Goeckerman therapy: a flawed analysis. 
  • Current diagnosis and treatment of interstitial pregnancy. 
  • Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. 
  • Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: effect on chronic graft-vs.-host disease and long-term survival. 
  • Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. 
  • Cytokine Biomarkers of Disease Activity and Therapeutic Response after Initiating Methotrexate Therapy in Patients with Juvenile Idiopathic Arthritis. 
  • Cytokinetically based induction chemotherapy and splenectomy for childhood acute nonlymphocytic leukemia. 
  • DHFR/MSH3 amplification in methotrexate-resistant cells alters the hMutSalpha/hMutSbeta ratio and reduces the efficiency of base-base mismatch repair. 
  • Decreased expression of nicotinamide phosphoribosyltransferase in patients with juvenile idiopathic arthritis receiving methotrexate. 
  • Decreased polyglutamylation of methotrexate in acute lymphoblastic leukemia blasts in adults compared to children with this disease. 
  • Delayed cardiac xenograft rejection in a pig-to-baboon model treated with a tolerance-inducing regimen and donor bone marrow infusion. 
  • Delayed-type hypersensitivity reaction with iscador M given in combination with cytotoxic chemotherapy. 
  • Developing comparative effectiveness studies for a rare, understudied pediatric disease: lessons learned from the CARRA juvenile localized scleroderma consensus treatment plan pilot study. 
  • Development of biomarkers to optimize pediatric patient management: what makes children different? 
  • Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma. 
  • Different patterns of relapse associated with three intensive treatment regimens for pediatric E-rosette positive T-cell leukemia: a Pediatric Oncology Group study. 
  • Differential reversal of lipophilic antifolate resistance in mammalian cells with modulators of the multidrug resistance phenotype. 
  • Dipyridamole-cisplatin potentiation: enhanced in vivo cytotoxicity in xenograft models of human testicular and bladder cancers. 
  • Disparities in Neurotoxicity Risk and Outcomes among Pediatric Acute Lymphoblastic Leukemia Patients. 
  • Dissimilar courses of twins with leukemia. 
  • Dose intensification of methotrexate and cytarabine during intensified continuation chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: POG 9406: a report from the Children's Oncology Group. 
  • Dosing Variation at Initiation of Adalimumab and Etanercept and Clinical Outcomes in Juvenile Idiopathic Arthritis: A Childhood Arthritis and Rheumatology Research Alliance Registry Study. 
  • Early results of intensified remission induction chemotherapy for childhood acute lymphocytic leukemia. 
  • Early rheumatoid arthritis. 
  • Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis. 
  • Effect of Low-Dose Methotrexate on eGFR and Kidney Adverse Events: A Randomized Clinical Trial. 
  • Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907. 
  • Effect of graft-versus-host disease prophylaxis on relapse in patients transplanted for acute myeloid leukemia. 
  • Effectiveness and toxicity of methotrexate in juvenile idiopathic arthritis: comparison of 2 initial dosing regimens. 
  • Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: the factor of the blood-brain barrier. 
  • Effects of continuous or discontinuous maintenance therapy on subsequent remission maintenance in childhood leukemia. 
  • Effects of cranial radiation in children with high risk T cell acute lymphoblastic leukemia: a Pediatric Oncology Group report. 
  • Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. 
  • Effects of pretransplant splenectomy and immunosuppression of humoral immunity in a pig-to-newborn goat cardiac xenograft model. 
  • Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3). 
  • Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1). 
  • Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience. 
  • Epigenetic regulation of human gamma-glutamyl hydrolase activity in acute lymphoblastic leukemia cells. 
  • Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial. 
  • Erosion of psoriatic plaques after chronic methotrexate administration. 
  • Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. 
  • Etanercept plus standard therapy for Wegener's granulomatosis. 
  • Evaluation of Biomarkers of Oxidative Stress and Apoptosis in Patients With Severe Methotrexate Neurotoxicity: A Case Series. 
  • Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study. 
  • Evaluation of daunorubicin (NSC-82151) and methotrexate (NSC-740) in combination as a remission maintenance regimen in the treatment of acute leukemia. 
  • Evaluation of the Effectiveness and Tolerability of Mycophenolate Mofetil and Mycophenolic Acid for the Treatment of Morphea. 
  • Evidence-based management of bullous pemphigoid. 
  • Extension study of participants from the trial of early aggressive therapy in juvenile idiopathic arthritis. 
  • F2-isoprostanes: a measure of oxidative stress in children receiving treatment for leukemia. 
  • FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. 
  • FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. 
  • Fibroblastic rheumatism: a report of 4 cases with potential therapeutic implications. 
  • Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944). 
  • Folate depletion and increased glutamation in juvenile idiopathic arthritis patients treated with methotrexate. 
  • Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. 
  • Fractionated total-body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase. 
  • Frontal fibrosing alopecia: a retrospective review of 19 patients seen at Duke University. 
  • Gaining insights into chronic natural killer cell leukemias through extensive characterization of an individual case. 
  • Genome-wide study of methotrexate clearance replicates SLCO1B1. 
  • Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. 
  • Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial. 
  • Graft-versus-host disease prophylaxis with methotrexate/cyclosporine in children with severe aplastic anemia treated with cyclophosphamide and HLA-identical marrow grafts. 
  • Guanosine triphosphate cyclohydrolase I regulates nitric oxide synthesis in renal proximal tubules. 
  • HLA- and genotype-based risk assessment model to identify infantile onset pompe disease patients at high-risk of developing significant anti-drug antibodies (ADA). 
  • Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis. 
  • Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis. 
  • High-dose methotrexate for primary CNS lymphoma in the elderly. 
  • High-risk gestational trophoblastic neoplasia with brain metastases: individualized multidisciplinary therapy in the management of four patients. 
  • Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation. 
  • Hypertensive reactions associated with paclitaxel. 
  • IgG and IgM anticardiolipin antibodies following treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. 
  • Immunology of inflammatory bowel disease: summary of the proceedings of the Subcommittee on Immunosuppressive Use in IBD. 
  • Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum. 
  • Impact of Childhood Leukemia Treatment on Attention Measured by the Continuous Performance Test Factor Structure. 
  • In vitro chemotherapy testing of transitional cell carcinoma. 
  • In vitro synergism between hybrid immunotoxins and chemotherapeutic drugs: relevance to immunotherapy of prostate carcinoma. 
  • Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. 
  • Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial. 
  • Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. 
  • Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. 
  • Infliximab in active early rheumatoid arthritis. 
  • Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. 
  • Infliximab treatment maintains employability in patients with early rheumatoid arthritis. 
  • Inhibition of DNA synthesis and enhancement of the uptake and action of methotrexate by low-power-density microwave radiation in L1210 leukemia cells. 
  • Initial Results from a Pilot Comparative Effectiveness Study of 3 Methotrexate-based Consensus Treatment Plans for Juvenile Localized Scleroderma. 
  • Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. 
  • Interaction of dihydrofolate reductase with methotrexate: ensemble and single-molecule kinetics. 
  • Interleukin-2 receptor levels in the sera of rheumatoid arthritis patients treated with methotrexate. 
  • International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. 
  • Intrinsic resistance to methotrexate in human soft tissue sarcoma cell lines. 
  • Islands of Inflammation: Neurosarcoidosis. 
  • Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia. 
  • Long-term follow-up of a randomized trial of graft-versus-host disease prevention by methotrexate/cyclosporine versus methotrexate alone in patients given marrow grafts for severe aplastic anemia. 
  • Long-term follow-up of three controlled trials comparing cyclosporine versus methotrexate for graft-versus-host disease prevention in patients given marrow grafts for leukemia. 
  • Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. 
  • Low-Dose Intravitreal Methotrexate for Proliferative Vitreoretinopathy. 
  • Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. 
  • Low-dose methotrexate results in the selective accumulation of aminoimidazole carboxamide ribotide in an erythroblastoid cell line. 
  • Lymphedema, musculoskeletal events and arm function in older patients receiving adjuvant chemotherapy for breast cancer (Alliance A171302). 
  • Lymphoblastic lymphoma in children--a randomized trial comparing LSA2-L2 with the A-COP+ therapeutic regimen: a Pediatric Oncology Group Study. 
  • Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate. 
  • Maculopathy as a complication of blood-brain barrier disruption in patients with central nervous system lymphoma. 
  • Marrow transplant experience for children with severe aplastic anemia. 
  • Marrow transplant experience in children with acute lymphoblastic leukemia: an analysis of factors associated with survival, relapse, and graft-versus-host disease. 
  • Marrow transplantation for leukemia following fractionated total body irradiation. A comparative trial of methotrexate and cyclosporine. 
  • Marrow transplantation for thalassaemia. 
  • Mathematical modeling of cell metabolism 
  • Measurement of methotrexate polyglutamates in human erythrocytes by ion-pair UPLC-MS/MS. 
  • Medical and surgical treatment of placenta percreta to optimize bladder preservation. 
  • Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry. 
  • Meningeal mycosis fungoides: clinical and cellular characteristics. 
  • Metabolomic Profiling to Identify Molecular Biomarkers of Cellular Response to Methotrexate In Vitro. 
  • Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. 
  • Methotrexate and cyclosporine for graft-vs.-host disease prevention: what length of therapy with cyclosporine? 
  • Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene. 
  • Methotrexate disposition, anti-folate activity and efficacy in the collagen-induced arthritis mouse model. 
  • Methotrexate recognition by the human reduced folate carrier SLC19A1. 
  • Methotrexate treatment for sarcoid-associated panuveitis. 
  • Methotrexate-associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis. 
  • Methotrexate-induced alterations in beta-oxidation correlate with cognitive abilities in children with acute lymphoblastic leukemia. 
  • Methotrexate: new uses for an old drug. 
  • Microwave treatment of intracerebral L1210 leukemia: schedule-dependent partial reversal of the effects of methotrexate. 
  • Minimal risk of chronic renal dysfunction in marrow transplant recipients treated with cyclosporine for 6 months. 
  • Modified LSA2-L2 treatment in 53 children with E-rosette-positive T-cell leukemia: results and prognostic factors (a Pediatric Oncology Group Study). 
  • Multiple drug chemotherapy regimen for patients with hormonally-unresponsive carcinoma of the prostate: a preliminary report. 
  • Neuropsychological effects of cranial radiation: current knowledge and future directions. 
  • Nicotinamide Phosphoribosyltransferase Attenuates Methotrexate Response in Juvenile Idiopathic Arthritis and In Vitro. 
  • Nicotinamide Phosphoribosyltransferase Deficiency Potentiates the Antiproliferative Activity of Methotrexate through Enhanced Depletion of Intracellular ATP. 
  • Ocular toxicity following high dose chemotherapy and autologous transplant. 
  • Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. 
  • Oral methotrexate for recurrent brain tumors in children: a Pediatric Oncology Group study. 
  • Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's). 
  • Oxidative changes in cerebral spinal fluid phosphatidylcholine during treatment for acute lymphoblastic leukemia. 
  • Oxidative stress and executive function in children receiving chemotherapy for acute lymphoblastic leukemia. 
  • Oxidative stress and neurobehavioral problems in pediatric acute lymphoblastic leukemia patients undergoing chemotherapy. 
  • PROMACE-MOPP and intrathecal chemotherapy for CNS lymphomas. 
  • Pancytopenia from using trimethoprim and methotrexate. 
  • Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry. 
  • Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate. 
  • Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907). 
  • Persistent and Prolonged Parvovirus B19 Viremia in a Pediatric Patient With Acute Lymphoblastic Leukemia. 
  • PharmGKB summary: methotrexate pathway. 
  • Pharmacogenomics in childhood rheumatic disorders: a foundation for future individualized therapy. 
  • Pharmacogenomics in pediatric rheumatology. 
  • Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. 
  • Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response. 
  • Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. 
  • Phase II study of adriamycin with sequential methotrexate and 5-fluorouracil (AMF) in gastric carcinoma. 
  • Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. 
  • Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. 
  • Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans. 
  • Pilot study of modified LMB-based therapy for children with ataxia-telangiectasia and advanced stage high grade mature B-cell malignancies. 
  • Pneumonitis complicating low-dose methotrexate therapy in rheumatoid arthritis. 
  • Prediction of disease relapse in a cohort of paediatric patients with localized scleroderma. 
  • Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. 
  • Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis. 
  • Preliminary evidence on abatacept safety and efficacy in refractory juvenile localized scleroderma. 
  • Primary biliary cirrhosis: new therapeutic directions. 
  • Profile of adalimumab and its potential in the treatment of uveitis. 
  • Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support. 
  • Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up. 
  • Prognostic index score and clinical prediction model of local regional recurrence after mastectomy in breast cancer patients. 
  • Progress in the treatment of rheumatoid arthritis. 
  • Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing. 
  • Prologue: 2019 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). 
  • Prolonged discordant xenograft survival and delayed xenograft rejection in a pig-to-baboon orthotopic cardiac xenograft model. 
  • Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. 
  • Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference. 
  • Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907. 
  • Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. 
  • Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. 
  • Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children's Oncology Group Studies P9904 and P9905. 
  • Randomized trial of cyclophosphamide, methotrexate, and 5-fluorouracil with or without estrogenic recruitment in women with metastatic breast cancer. 
  • Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA. 
  • Red blood cell folate concentrations and polyglutamate distribution in juvenile arthritis: predictors of folate variability. 
  • Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. 
  • Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. 
  • Reverse Translation in Advancing Pharmacotherapy in Pediatric Rheumatology: A Logical Approach in Rare Diseases with Limited Resources. 
  • Risk factors for acute graft-versus-host disease associated with cyclosporine and methotrexate prophylaxis. 
  • Risk factors for airflow obstruction in recipients of bone marrow transplants. 
  • Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. 
  • Role of folylpolyglutamates in biochemical modulation of fluoropyrimidines by leucovorin. 
  • SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. 
  • Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results. 
  • Second central nervous system prophylaxis in children with acute lymphoblastic leukemia who relapse after elective cessation of therapy. 
  • Seesaw nystagmus following whole brain irradiation and intrathecal methotrexate. 
  • Serial carcinoembryonic antigen assays in patients with metastatic carcinoma of prostate being treated with chemotherapy. 
  • Study on the comparability of 6 versus 12 cycles of adjuvant cyclophosphamide, methotrexate, and fluorouracil. 
  • Subacute methotrexate neurotoxicity and cerebral venous sinus thrombosis in a 12-year-old with acute lymphoblastic leukemia and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: homocysteine-mediated methotrexate neurotoxicity via direct endothelial injury. 
  • Successful treatment of a cervical pregnancy with a single low dose methotrexate regimen. 
  • Successful treatment of pediatric histiocytic sarcoma using abbreviated high-risk leukemia chemotherapy. 
  • Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial. 
  • Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. 
  • Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis. 
  • Systemic chemotherapy for urothelial cancer. 
  • Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). 
  • Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. 
  • Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. 
  • Targeting Ras signaling through inhibition of carboxyl methylation: an unexpected property of methotrexate. 
  • Ten years' experience with LSA2-L2 therapy for childhood advanced lymphoblastic lymphoma. 
  • The Duke AFM Program. Intensive induction chemotherapy for metastatic breast cancer. 
  • The Future Is Now: Biologics for Non-Infectious Pediatric Anterior Uveitis. 
  • The development of chronic graft-versus-host disease: an analysis of screening studies and the impact of corticosteroid use at 100 days after transplantation. 
  • The effect of genotype on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug response. 
  • The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis. 
  • The importance of an isolated central nervous system relapse in children with acute lymphoblastic leukemia. 
  • The pathophysiology and treatment of graft-versus-host disease. 
  • The pharmacology of methotrexate. 
  • The potential of monoclonal antibodies as carriers of radiation and drugs for immunodetection and therapy of brain tumors. 
  • Therapeutic approaches to the treatment of rheumatoid disease. 
  • Topical methotrexate therapy for psoriasis. 
  • Transcriptional profiles of JIA patient blood with subsequent poor response to methotrexate. 
  • Transitional cell carcinomatous meningitis after M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) chemotherapy. 
  • Treatment approaches to juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey. 
  • Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival. 
  • Treatment of high-stage bladder cancer: case for adjunctive chemotherapy. 
  • Treatment of isolated primary intraocular lymphoma with high-dose methotrexate-based chemotherapy and binocular radiation therapy: a single-institution experience. 
  • Treatment of juvenile idiopathic arthritis-associated uveitis: challenges and update. 
  • Treatment of lymphohistiocytic erythrophagocytosis with VP-16 and aziridinylbenzoquinone. 
  • Treatment of rheumatoid arthritis with a DR4/1 peptide. 
  • Treatments and outcomes in high-risk gestational trophoblastic neoplasia: A systematic review and meta-analysis. 
  • Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. 
  • Uveitis in children. 
  • Value of cyclophosphamide or melphalan as combined chemotherapy in hormonally unresponsive prostatic carcinoma. 
  • Vasculitis and Pregnancy. 
  • What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? 
• 

  Keywords of People

  • Allen, Nancy Bates, Professor Emeritus of Medicine, Medicine, Rheumatology and Immunology
  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology